Darunavir/cobicistat

Darunavir/cobicistat, sold under the brand names Prezcobix (US) and Rezolsta (EU), is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS.^[3] It contains darunavir and cobicistat.^[3][5][6] Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.^[6][3]

Darunavir/cobicistat

Combination of
Darunavir	HIV protease inhibitor
Cobicistat	Cytochrome P450 (CYP3A) inhibitor
Clinical data
Trade names	Rezolsta, Prezcobix
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Prezcobix
Pregnancy category	AU: B2[1]
Routes of administration	By mouth
ATC code	J05AR14 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only[2] US: ℞-only[3] EU: Rx-only[4]
Identifiers
CAS Number	206361-99-1 Y 1004316-88-4 Y
PubChem CID	57327017
UNII	YO603Y8113 LW2E03M5PG Y
KEGG	D10832
Chemical and physical data
Formula	C67H90N10O12S3
Molar mass	1323.70 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N.CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
InChI InChI=1S/C40H53N7O5S2.C27H37N3O7S/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35;1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49);3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t32-,33-,36+;22-,23-,24+,25-,26+/m10/s1 Key:CXORHDVSJFELCV-HWDLLDTBSA-N

Darunavir/cobicistat was approved for use in the European Union in November 2014, and for use in the United States in January 2015.^{[4][7][8][3][9]}